These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34405747)

  • 1. Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations.
    Hecker JS; Pachzelt L; Götze KS
    Expert Rev Hematol; 2021 Sep; 14(9):789-793. PubMed ID: 34405747
    [No Abstract]   [Full Text] [Related]  

  • 2. An early glimpse at azacitidine plus venetoclax for myelodysplastic syndromes.
    Pleyer L; Sekeres MA
    Lancet Haematol; 2022 Oct; 9(10):e714-e716. PubMed ID: 36063831
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospects for Venetoclax in Myelodysplastic Syndromes.
    Garcia JS
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
    Gangat N; McCullough K; Johnson I; Al-Kali A; Begna KH; Patnaik MM; Litzow MR; Hogan W; Shah M; Alkhateeb H; Mangaonkar A; Foran JM; Badar T; Palmer JM; Sproat L; Arana Yi CY; Pardanani A; Tefferi A
    Am J Hematol; 2022 Jun; 97(6):E214-E216. PubMed ID: 35303376
    [No Abstract]   [Full Text] [Related]  

  • 5. Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective.
    Gangat N; Komrokji RS; Tefferi A
    Am J Hematol; 2023 Feb; 98(2):225-228. PubMed ID: 36377194
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.
    Komrokji RS; Singh AM; Ali NA; Chan O; Padron E; Sweet K; Kuykendall A; Lancet JE; Sallman DA
    Blood Cancer J; 2022 Nov; 12(11):148. PubMed ID: 36329025
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.
    Gruszczynska A; Maiti A; Miller CA; Ramakrishnan SM; Link DC; Uy GL; Petti AA; Hayes K; DiNardo CD; Ravandi F; Ley TJ; Spencer DH; Gao F; Konopleva MY; Welch JS
    Haematologica; 2024 Aug; 109(8):2653-2659. PubMed ID: 38618679
    [No Abstract]   [Full Text] [Related]  

  • 8. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
    Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with
    Wang X; Xiao Z; Qin T; Xu Z; Jia Y; Qu S; Li B; Pan L; Gao Q; Jiao M; Gale RP
    Hematology; 2024 Dec; 29(1):2338509. PubMed ID: 38597818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.
    Liu B; Guo Y; Deng L; Qiao Y; Jian J
    Hematology; 2020 Dec; 25(1):414-423. PubMed ID: 33191860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Venetoclax combined with azacitidine in the treatment of elderly patients with acute myeloid leukemia or myeloid sarcoma: Three cases reports and literature review].
    Tian FQ; Zhang LS; Li JH; Tang MQ; Jiang J; Cheng XH; Zhang XC; Jiang M
    Zhonghua Xue Ye Xue Za Zhi; 2020 Aug; 41(8):694-696. PubMed ID: 32942828
    [No Abstract]   [Full Text] [Related]  

  • 14. Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience.
    Azizi A; Ediriwickrema A; Dutta R; Patel SA; Shomali W; Medeiros B; Iberri D; Gotlib J; Mannis G; Greenberg P; Majeti R; Zhang T
    Leuk Lymphoma; 2020 Nov; 61(11):2700-2707. PubMed ID: 32543932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.
    Niscola P; Noguera NI; Catalano G; Cupelli L; Fratoni S; Giovannini M; Mazzone C; Neri B; Scaramucci L; Trawinska MM; de Fabritiis P; Abruzzese E
    Acta Oncol; 2019 Jun; 58(6):888-890. PubMed ID: 30848978
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].
    Zong LH; Wu XX; Zhang J; Li MY; Song BQ; Kong JY; Kong X; Hu XH; Bao XB; Qiu HY; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):861-864. PubMed ID: 34788928
    [No Abstract]   [Full Text] [Related]  

  • 17. Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
    Xia L; Tian W; Zhao Y; Jiang L; Qian W; Jiang L; Ge L; Li J; Jin F; Yang M
    Signal Transduct Target Ther; 2023 May; 8(1):176. PubMed ID: 37130896
    [No Abstract]   [Full Text] [Related]  

  • 18. Azacitidine and Venetoclax in AML.
    Moore JW; Pelcovits A; Reagan JL
    N Engl J Med; 2020 Nov; 383(21):2088. PubMed ID: 33207105
    [No Abstract]   [Full Text] [Related]  

  • 19. Azacitidine and Venetoclax in AML.
    Lucijanic M
    N Engl J Med; 2020 Nov; 383(21):2087-2088. PubMed ID: 33207104
    [No Abstract]   [Full Text] [Related]  

  • 20. Azacitidine and Venetoclax in AML.
    Chitikela S; Kumar L; Sahoo RK
    N Engl J Med; 2020 Nov; 383(21):2087. PubMed ID: 33207103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.